All sponsors

CSL Behring

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS10
PHASE 3 / 2-36
RECRUITING9
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO25%

Delay Index: of 8 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +1.5 months). See all sponsors →

Open CSL Behring on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
BE1116
NCT07094087
P3RecruitingComplex Cardiovascular Surgery With Cardiopulmonary Bypass2002027-04-06 (-2 mo)
CSL511 Fibrinogen concentrate (human)
NCT06617897
P3RecruitingAcquired Fibrinogen Deficiency902027-06-30 (+10 mo)
CSL889
NCT06699849
P2RecruitingSickle Cell Disease Vaso-occlusive Crisis702027-10-22 (-5 mo)
Vamifeport
NCT07332091
P2Active, not recruitingHomeostatic Iron Regulator Gene-related Hereditary Hemochromatosis842028-04-15
Anumigilimab
NCT07224360
P2RecruitingSickle Cell Disease632028-08-15 (+2 mo)
CSL222 (AAV5-hFIXco-Padua)
NCT06003387
P3RecruitingHemophilia B352028-10-04
CSL787
NCT07048262
P2RecruitingNon-cystic Fibrosis Bronchiectasis1802029-05-06 (+14 mo)
POSIBIL6ESKD
NCT05485961
P2/3RecruitingEnd Stage Kidney Disease31102029-05-22 (+6 mo)
IgPro20
NCT07648264
P3RecruitingSecondary Immune Deficiency632029-09-27
IX-TEND 3004
NCT07080905
P3RecruitingHemophilia B202033-10-24